Ahluwalia M B, Rotstein J, Tatematsu M, Roomi M W, Farber E
Carcinogenesis. 1983;4(1):119-21. doi: 10.1093/carcin/4.1.119.
This study was undertaken to observe whether the administration of reduced glutathione intragastrically to male Fischer 344 rats during the precancerous steps of liver carcinogenesis has any protective effect on the development of hepatocellular carcinoma. Hepatocyte nodules were induced in the liver with a single initiating dose of diethylnitrosamine followed by selection of resistant hepatocytes to generate nodules by a two week exposure to dietary 2-acetylaminofluorene coupled with partial hepatectomy. Animals had hepatocyte ('hyperplastic') nodules when examined by laparotomy at three months. At that time, the animals were divided into two groups. One received daily intragastric glutathione for 8 months while the other received no further treatment. An additional control group received only the selecting (promoting) regimen with no initiator or glutathione. At 12 months, the animals receiving the initiator and promoter regimen had a 65% incidence of hepatocellular carcinoma and those receiving glutathione in addition had a 71% incidence. Under these experimental conditions, the long term administration of glutathione appears to have no observable influence on liver cancer development in this model.
本研究旨在观察在雄性Fischer 344大鼠肝癌发生的癌前阶段经胃给予还原型谷胱甘肽是否对肝细胞癌的发生有任何保护作用。用单次起始剂量的二乙基亚硝胺诱导肝脏中的肝细胞结节，然后通过两周暴露于含2-乙酰氨基芴的饮食并结合部分肝切除术来选择抗性肝细胞以生成结节。三个月时通过剖腹术检查，动物有肝细胞（“增生性”）结节。此时，将动物分为两组。一组每天经胃给予谷胱甘肽8个月，而另一组不接受进一步治疗。另一个对照组仅接受选择（促进）方案，不使用起始剂或谷胱甘肽。12个月时，接受起始剂和促进剂方案的动物肝细胞癌发病率为65%，另外接受谷胱甘肽的动物发病率为71%。在这些实验条件下，长期给予谷胱甘肽似乎对该模型中的肝癌发生没有可观察到的影响。
